Cite Them Right 11th edition - Harvard

Kocsmár, I., Kocsmár, Éva, Pajor, G., Kulka, J., Székely, E., Kristiansen, G., Schilling, O., Nyirády, P., Kiss, A., Schaff, Z., Riesz, P. und Lotz, G. (2022) Addition of chromosome 17 polysomy and HER2 amplification status improves the accuracy of clinicopathological factor-based progression risk stratification and tumor grading of non-muscle-invasive bladder cancer [cd]. Freiburg: Universität. doi:10.3390/cancers14194570.

Chicago Manual of Style 17th edition (full note)

Kocsmár, Ildikó, Éva Kocsmár, Gábor Pajor, Janina Kulka, Eszter Székely, Glen Kristiansen, Oliver Schilling, Péter Nyirády, András Kiss, Zsuzsa Schaff, Péter Riesz, und Gábor Lotz. Addition of chromosome 17 polysomy and HER2 amplification status improves the accuracy of clinicopathological factor-based progression risk stratification and tumor grading of non-muscle-invasive bladder cancer. Cd. Freiburg: Universität, [2022?], Freiburg: Universität, [2022?]. https://doi.org/10.3390/cancers14194570.

American Psychological Association 7th edition

Kocsmár, I., Kocsmár, Éva, Pajor, G., Kulka, J., Székely, E., Kristiansen, G., Schilling, O., Nyirády, P., Kiss, A., Schaff, Z., Riesz, P., & Lotz, G. (ca. 2022). Addition of chromosome 17 polysomy and HER2 amplification status improves the accuracy of clinicopathological factor-based progression risk stratification and tumor grading of non-muscle-invasive bladder cancer [Cd]. Universität. https://doi.org/10.3390/cancers14194570

Modern Language Association 9th edition

Kocsmár, I., Éva Kocsmár, G. Pajor, J. Kulka, E. Székely, G. Kristiansen, O. Schilling, P. Nyirády, A. Kiss, Z. Schaff, P. Riesz, und G. Lotz. Addition of chromosome 17 polysomy and HER2 amplification status improves the accuracy of clinicopathological factor-based progression risk stratification and tumor grading of non-muscle-invasive bladder cancer. cd, Universität, 2022, https://doi.org/10.3390/cancers14194570.

ISO-690 (author-date, Deutsch)

KOCSMÁR, Ildikó, Éva KOCSMÁR, Gábor PAJOR, Janina KULKA, Eszter SZÉKELY, Glen KRISTIANSEN, Oliver SCHILLING, Péter NYIRÁDY, András KISS, Zsuzsa SCHAFF, Péter RIESZ und Gábor LOTZ, 2022. Addition of chromosome 17 polysomy and HER2 amplification status improves the accuracy of clinicopathological factor-based progression risk stratification and tumor grading of non-muscle-invasive bladder cancer. Freiburg: Universität

Achtung: Diese Zitate sind unter Umständen nicht zu 100% korrekt.